Trial Profile
Efficacy of PD-1 inhibitors nivolumab in patients with metastatic non-small cell lung cancer (NSCLC) with KRAS or EGFR T790M mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Lung cancer; Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 22 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology